Abstract
Our study aimed to comprehensively investigate the genetic polymorphisms of CYP3A4 in Han Chinese. We sequenced the gene regions of CYP3A4, including its promoter, exons, surrounding introns and 3′ untranslated region (3′UTR), from 100 unrelated-healthy Han Chinese individuals. We detected 11 SNPs, three of which are novel. According to in silico functional prediction of novel variants, 20148 A>G in exon 10, resulting in substitution of Tyr319 with Cys (CYP3A4*21), may induce dramatic alteration of protein conformation, and 26908 G>A in 3′UTR may disrupt post-transcriptional regulation. We identified five alleles in Han Chinese, the allele frequencies of CYP3A4*1, *5, *6, *18 and *21 are 97, 0.5, 1, 1 and 0.5%, respectively. Haplotype inference revealed 14 haplotypes, of which the major haplotype CYP3A4*1A constitutes 59% of the total chromosomes. We also examined the possible role of natural selection in shaping the variation of CYP3A4 and confirmed a trend, consistent with the action of positive selection. We systematically screened the genetic polymorphisms of CYP3A4 in Han Chinese, highlighted possible functional impairment of the novel allele and summarized the distinct allele and haplotype frequency distribution, with an emphasis on detecting the footprint of recent positive selection on the CYP3A4 gene in Han Chinese.
Similar content being viewed by others
Introduction
Cytochrome P450 3A4 (CYP3A4, MIM 124010), together with CYP3A5 (MIM 605325), CYP3A7 (MIM 605340) and CYP3A43 (MIM 606534), are members of the CYP3A subfamily forming a gene cluster on chromosome 7q22. CYP3A4, as the most abundantly expressed P450 isoenzyme in human liver, contributes to the oxidative metabolism of approximately 50% of clinically-used drugs, with a broad range of substrate specificity. For instance, CYP3A4 is involved in the oxidation of certain antibiotics, calcium channel blockers, antidepressants, immunosuppressants, HMG-CoA reductase inhibitors (HMGs), antihistamines and protease inhibitors, as well as some endogenous steroids, such as cortisol, testosterone and estradiol.
The enzyme activity of CYP3A4 shows wide interindividual variability (up to 60-fold),1 resulting in therapeutic failure, unpredictable adverse side effects or severe drug toxicity. The enormous variation observed in drug metabolism is mainly due to the combined effect of genetic polymorphisms, regulation of gene expression and interaction with drugs or environmental chemicals.2 Genetic polymorphisms, accounting for as much as 90% of interindividual variability in CYP3A4 activity,3 are therefore of clinical value in predicting an individual's ability to respond to certain therapeutic agents. Moreover, CYP3A4 polymorphisms can also assist prediction of disease predisposition.4 CYP3A4*1B allele (CYP3A4-V, rs2740574), a −392A>G transition in the promoter region, has been reported to be significantly associated with HIV infection;5 this allele can also result in an increased risk of estrogen negative breast cancer6 and prostate cancer;4, 7, 8 CYP3A4*4 allele with the substitution of Ile118Val is significantly associated with the prevalence of type 2 diabetes mellitus;9 CYP3A4*18 allele which contains a Leu293Pro substitution has also been shown to be associated with low bone mineral density and increased prostate cancer risk.4, 10
Given these important clinical implications, genetic polymorphisms of CYP3A4 are extensively studied in different ethnic populations and exhibit remarkable interethnic difference in distribution and frequency spectrum. Thus far, a total of 20 allelic variants have been identified and characterized (http://www.imm.ki.se/CYPalleles/cyp3a4.htm), eight of which lead to reduced catalytic activity or functional deficiency in vitro. The most prevalent variant is CYP3A4*1B, with allele frequency ranging from 0∼4% in Asians and Europeans to 82% in Africans.11, 12 The elimination of CYP3A4*1B in non-African populations has been suggested to be a consequence of selective advantage.13 This variant might moderately enhance CYP3A4 gene expression, by virtue of reduced binding ability of a transcriptional repressor.14 CYP3A4*18 is the most frequent variant in Asian populations (about 1% in Chinese, 1.3% in Japanese and 2.1% in Malaysian),15, 16, 17, 18 but absent both in Caucasians and Africans. One recently discovered rare variant, CYP3A4*20—with a premature stop codon yielding a truncated protein and completely devoid of functional activity—occurs less than 0.06% in Caucasians19 and has not been reported in Asians or Africans.
Han Chinese is the largest single ethnic group in the world, constituting over 92% of the population of mainland China and about 19% of the global human population. Han Chinese has significant internal difference as a result of ongoing demographic expansion, accompanied by assimilation of various regional ethnicities and tribes,20, 21, 22, 23 which can be divided into two genetically differentiated groups, northern Han and southern Han, separated by the Yangtze River.20, 21, 22 Hitherto, only a few studies focused on single-nucleotide polymorphism (SNP) prevalence analysis of CYP3A4 in Han Chinese. Hsieh et al.24 firstly screened SNPs in 102 Taiwan Chinese by PCR-single-strand conformation polymorphism and restriction fragment length polymorphism. Nevertheless, Taiwan Chinese are not appropriate to serve as a good representative for Han Chinese in mainland. Then, Wen and Liu et al.11, 25 surveyed polymorphisms of CYP3A4 in Chinese by genotyping, a method that cannot detect novel alleles which might be specific to Han Chinese. Recently, Du et al.26 used direct sequencing, but with a small amount of sample (20 Han Chinese). Therefore, the genetic polymorphisms of CYP3A4 gene in Han Chinese are far from being studied thoroughly, and more investigation of CYP3A4 polymorphisms in Han Chinese is imperatively needed.
Considering the ethnic-specific distribution of genetic polymorphisms and their important roles in optimizing therapeutic efficiency and modifying clinical presentation, we screened CYP3A4 variants in 100 Han Chinese individuals by direct sequencing. All of our samples are collected in Beijing, which is a good representative of northern Han. And we also estimated allele and genotype frequencies, reconstructed haplotypes and analyzed functional activity of novel polymorphisms.
Materials and methods
Subjects and genomic DNA extraction
A total of 100 cell lines of unrelated healthy individuals (51 male and 49 female) of Han Chinese ancestry were obtained from two sources: Han Chinese in Beijing from the HapMap Project27 (42 cell lines) and blood samples of unrelated Han Chinese individuals in Beijing (remaining 58 cell lines).28 The 58 participants (30 male and 28 female; mean age 26) were judged to be in healthy condition, based on a physical examination. Before blood and information collection, the participants signed informed consent forms. To ensure their Han Chinese origin, they were interviewed regarding their ancestral status for up to three previous generations. The project was approved by the Ethnical Committee at the Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
We used salting-out method to extract genomic DNA from Epstein-Barr virus-transformed lymphoblastoid cells, established from peripheral blood.29
PCR amplification and sequencing
To screen the SNPs in CYP3A4, we sequenced gene regions, including its promoter, exons, surrounding introns and 3′ untranslated region (3′UTR). The PCR was performed in a volume of 15 μl, containing 30 ng of genomic DNA, 1 × PCR TaKara buffer (Mg2+ plus), 2.5 pmol of each primer, 25 pmol dNTPs and 1 unit of Taq DNA polymerase (TaKara Bio, Dalian, China). The cycling program was initiated with heat denaturation at 95 °C for 5 min, followed by 30 cycles of 94 °C for 30 s, 55–60 °C for 30 s, 72 °C for 1 min and a final extension at 72 °C for 10 min, using a thermal cycler (GeneAmp PCR System 9700, Applied Biosystems, Foster City, CA, USA). The PCR products were enzymatically purified using shrimp alkaline phosphatase (SAP; Amersham Biosciences, NJ, USA), followed by incubation at 37 °C for 60 min, after which the shrimp alkaline phosphatase enzyme was inactivated at 85 °C for 15 min. Then the purified PCR products were subjected to direct sequencing by using the DYEnamic ET terminator cycle sequencing kit (GE Healthcare, Chalfont St Giles, UK) on the ABI Prism 3730xl DNA Analyzer (Applied Biosystems). All the PCR and sequencing primers were listed in Supplementary Table S1. Singleton mutations, occurring only once in 100 samples, were verified with a new PCR amplification, followed by bidirectional sequencing with coverage of the SNP.
Data analysis
We used Phred, Phrap, Consed and Polyphred programs (University of California; http://elcapitan.ucsd.edu/hyper/polyphred.usage.html) for base calling, quality assessment and polymorphism determination from DNA sequencing.30, 31, 32, 33 Genetic polymorphisms of CYP3A4 gene were named according to the genomic reference sequence AF280107.1.
We employed Haploview4.1 (BROAD Institute; http://www.broad.mit.edu/mpg/haploview/) to estimate allele frequencies, test Hardy–Weinberg equilibrium and analyze linkage disequilibrium (LD) structure.34 LD structure was displayed by GOLD heatmap color scheme,35 and LD blocks were defined by the ‘solid spine of LD’ algorithm,34 with a minimum D’ value of 0.9.
We used PHASE2.1 (University of Washington; http://www.stat.washington.edu/stephens/phase.html) for haplotype reconstruction and haplotype frequency estimation.36, 37
We used PITA,38 an miRNA target prediction algorithm based on hybridization energy and site accessibility, to predict potential miRNAs that target CYP3A4 and harbor certain SNP in their binding sites.
We combined two prediction programs, PANTHER (the National Institute of General Medical Sciences; http://www.pantherdb.org/)39, 40 and PolyPhen (Brigham and Women's Hospital, Harvard University; http://genetics.bwh.harvard.edu/pph/),41 to predict possible impact of novel nonsynonymous SNP on protein function in the consideration of both sequence similarity and structural information. PANTHER subPSEC scores <−3.0 (Pdeleterious>0.5) and PolyPhen PSIC score difference >2.0 indicate mutations as probably damaging protein function.39, 40, 41 PyMOL 0.99rc6 (Delano Scientific LLC.; http://www.pymol.org/) was utilized for visualization of CYP3A4 three-dimentional structure (PDB ID: 2J0D),42 which was downloaded from the RCSB Protein Data Bank (PDB, http://www.rcsb.org/pdb/home/home.do). CASTp (Computed Atlas of Surface Topography of proteins, http://sts-fw.bioengr.uic.edu/castp/calculation.php) was employed for protein pocket identification and measurement of pocket volume change influenced by novel amino acid substitution.43
We performed multiple neutrality tests using DnaSP v5 (http://www.ub.edu/dnasp/)44 to detect evidence of positive selection on the CYP3A4 gene. Tajima's D (TD),45 Fu and Li's F (FL-F)46 (with a chimpanzee sequence as outgroup), and Fay and Wu's H (FW-H)47 (also with outgroup) were calculated by a sliding window of 25 bp to test for deviations from a neutral equilibrium frequency distribution at all loci. We additionally investigated evidence for natural selection by examining the integrated haplotype score (iHS)48 that was obtained from the program haplotter (http://haplotter.uchicago.edu/).
Results and discussion
Allele and genotype frequency of CYP3A4 in Han Chinese
We detected 11 genetic variants in Han Chinese, with allele frequencies complied well with the Hardy–Weinberg equilibrium (P>0.05), which include two in promoter, four in exons, three in introns and two in 3′UTR (Table 1). Of the 11 genetic variants, three novel polymorphisms were identified, they are 4231 A>C in intron2, 20148 A>G in exon 10 and 26908 G>A in 3′UTR. Most of the CYP3A4 polymorphisms in Han Chinese are relatively rare: nine SNPs occur below a frequency of 5%, except two commonly SNPs, rs28969391 (32.5%) and rs2242480 (25%). rs28969391 is a 26707T deletion in the 3′UTR with little chance to be involved in the post-transcriptional regulation, as it is situated in a region not targeted by any known human miRNAs according to PITA prediction. Indeed, SNPs in miRNA target sites rarely reach such a high frequency, as they are usually subjected to more stringent functional constraints and would be removed by purifying selection eventually.49, 50 rs2242480 is located in the 10th intron, 12 nt downstream of the donor site (IVS10+12). This polymorphism has been reported to increase the lipid-lowering efficacy of atorvastatin,51 although it remains unclear whether splicing efficiency would be influenced in the presence of a G>A mutant, adjacent to 5′ splice site.
Moreover, five alleles were identified in Han Chinese, they are CYP3A4*1, *5, *6, *18 and *21, with occurrence of 97, 0.5, 1, 1 and 0.5%, respectively (Table 2). We further compared allele frequencies of CYP3A4 among different ethnic groups and demonstrated remarkable interpopulation difference, with regard to allelic distribution (Table 3). CYP3A4*1B, the most frequent allele in Africans (82%),12 has significantly lower incidence in Caucasians (4%)12, 52 and is near extinction in Asians.53, 54 This allele is present in about 0.5% of Han Chinese population, a higher incidence than in Malays18 and Japanese.54 The top two frequent alleles estimated in Chinese by Du et al., CYP3A4*15 (16%) and *14 (7%), were neither detected in our samples. The significant differences of allele frequencies between the two investigations may result from involvement of ethnic minorities in Du’s samples (consisting of 20 Han, 30 She and 10 Dong subjects) and substantial genetic diversity within Han Chinese. In our Han Chinese population, CYP3A*18 remains the most common coding variant, which is in agreement with previous investigations in Asian populations.15, 16, 17, 18, 54
Among seven observed genotypes (Table 2), the wild type absolutely predominates in Han Chinese, accounting for approximately 94% of the populations; the other six genotypes—heterozygous *1/*1B, *1/*5, *1/*6, *1/*18, *1/*21 and *6/*18—each contributes an insignificant percentage (1%). The low prevalence of mutant genotypes indicates relative infrequency of poor metabolizer in Han Chinese, which is in line with previously reported low-frequency of CYP3A4 poor metabolizer in Asians.55
Haplotypes of CYP3A4 in Han Chinese
Haplotypes were inferred with 11 detected SNPs by the PHASE program. Our reconstruction of haplotypes strengthened previous findings that a few common haplotypes of CYP3A4 occupy a huge proportion of the total chromosomes examined,54 whereas a large subset of haplotypes carries low levels of variation.56 Of 14-phased haplotypes (Figure 1), two major haplotypes, CYP3A4*1A and *1v, constitute 59 and 19.5% of the total haplotype diversity, respectively, whereas 11 haplotypes occur at a frequency below 5%, bearing no more than three variants.
Seven haplotypes labeled with small alphabetical letters were newly assigned (Figure 1). Haplotype inference revealed the involvement of novel polymorphisms in CYP3A4*1u, *1w and *21: haplotype of *1u contains novel substitution of A>C at nucleotide position 4231; the *1w haplotype is composed of 20230G>A, 26707T>- and new variant 26908G>A; and novel allele *21 harbors nonsynonymous SNP 20148A>G in exon 10, resulting in Cys taking the place of Tyr at amino acid 319 (Y319C).
According to haplotype combinations, CYP3A4 haplotypes containing the IVS10+12G allele (such as *1A) show strong linkage with CYP3A5*3, whereas 88% of the CYP3A4 haplotypes with the IVS10+12A allele (such as *1G) are tightly linked to CYP3A5*1 in Japanese.54 The close linkage of haplotypes between CYP3A4 and CYP3A5 was also demonstrated in Chinese populations,57 which indicates that genotyping at the IVS10+12 position in CYP3A4 might be easy to predict the existence of CYP3A5*3.54 We observed about 75% of CYP3A4 haplotypes carry the IVS10+12G allele, implying a large proportion of CYP3A5*3 in the Han Chinese population.
The novel nonsynonymous SNP altering enzyme function
The substitution of Cys for Tyr in codon 319 (Y319C) lies on the helix I,42 a domain which flanks the heme group and contains a substrate recognition site (SRS4).58 As shown in the Supplementary Table S2, Tyr319 is a highly conserved residue in the cytochrome P450 family throughout eukaryote evolution from nematode to human. In order to predict the functional impact of the amino acid mutation, we used two in silico prediction algorithms, PolyPhen and PANTHER, which combine protein structure and sequence evolution analysis to achieve a more comprehensive result. According to PANTHER prediction, the Y319C variant stands a good chance of impairing the protein function with low subPSEC score (−6.90091) and significantly high Pdeleterious value (0.98018). Likewise, the variant was also considered to be probably damaging, because of the enlarging of a cavity based on PolyPhen analysis (PSIC score difference=3.453). The CASTp analysis provided us with a better understanding of the fatal transformation in cavity resulting from the nonsynonymous SNP (Figures 2a and b). The wild-type cavity (Pocket ID=144) covers 89.4 Å2 of surface area and has a volume of 135.08 Å3, which is composed of atoms from 10 residues: Tyr319, Glu320, Leu366, Phe367, Tyr399, Arg403, Glu412, Pro474, Leu475 and Leu477 (Figure 2a). Surprisingly, the replacement of Tyr319 with Cys yields an increase in surface area of 270.1 Å2 and a three-fold expansion in volume (Pocket ID=158, surface area=359.5Å2, volume=376.86Å3). The dramatic change of cavity in the mutant is due to recruitment of atoms from additional 11 residues: Thr323, Pro467, Glu470, Thr471, Gln472, Ile473, Lys487, Pro488, Val489, Val490 and Leu491 (Figure 2b).
Furthermore, Tyr319 has a critical role in maintaining perfect position of the loop between β3-3 and β4-1. This β-β loop is held in place through four extra loop hydrogen bonds (Figure 2c). Two of them are formed from Tyr319 to the oxygen atom of Gln472 and the nitrogen atom of Leu475, with bond lengths of 3.01 and 3.05 Å, respectively, whereas the other two are donated by the bonding interactions between Ile369 and Leu483, and between Leu172 and Val489, respectively. The three-dimensional structure of the β-β loop in Figure 2c showed that the center of the loop (L477-P485) is available for approaching ligands, termed as a ligand-accessible region.59 Both X-ray structure analysis and molecular modeling for CYP3A4 have revealed ligand inducible of heme pocket and extreme flexibility of ligand-accessible regions, so that diverse substrates can be accommodated in active site by adopting multiple ligand-bound conformations.42, 59 From this point of view, Tyr319 together with Leu172 and Ile369, might act as anchors of the β-β loop, not only keeping the flexibility of the loop for its participation in the regulation of the heme pocket size when interacting with various drugs, but also restrict the freedom of the loop to avoid ligand-accessible region losing connection from ligands. Thus, once Tyr319 is replaced by Cys, its interaction with Gln472 and Leu475 will be abolished (Figure 2d), leaving only two hydrogen bonds unable to adjust and stabilize the β-β loop.
Therefore, the highly conserved residue in important domain, together with striking alteration in cavity configuration as a result of this single amino acid substitution, raises the possibility of producing malfunction protein by the new variant.
The novel SNP in 3′UTR influencing miRNA post-transcriptional regulation
We detected a new polymorphism, which is a G-to-A transition at nucleotide position 26908 located in the 3′UTR region. Accumulating evidence revealed that variants in the 3′UTR could be functional impairment if they happen to be located in miRNA-binding sites,49, 60 because SNPs will interfere with miRNA function and result in loss of miRNA-mediated regulation of drug metabolism genes. For this reason, we employed PITA to predict liver-expressed miRNAs,61, 62, 63, 64, 65 whose binding sites harbor this polymorphism site. A total of 14 miRNAs containing complementary site of the SNP in their seed sequences meet the threshold of interaction energy for miRNA:target pairing (ΔΔG⩽−5 kcal/mol) (Table 4, Supplementary Figure S1). The strengthened or declined miRNA binding caused by SNP variations may have consequences of corresponding downregulation or upregulation of mRNA stability and translation.66, 67 Therefore, the novel polymorphism in predicted miRNA target sites may be a candidate causal variant responsible for altering expression of CYP3A4 protein.
Footprint of positive selection on CYP3A4 in Han Chinese
In non-African populations, the CYP3A locus was reported under strong positive selection,13, 56 leading to sudden loss of neutral genetic variation when beneficial alleles arise nearby. The near-fixation frequency of derived alleles of both CYP3A4*1B and CYP3A5*3, coupled with their unusually geographic patterns correlating with latitude, were thought to be results of salt homeostasis and rickets, the underlying selecting factors in European, Caucasians and Asians.13, 56 In Han Chinese, we also observed a number of characteristic features in sequence variations: low polymorphism levels with a fraction of high-frequency-derived alleles, a marked skew toward rare variants and dramatic differences in allele frequency between Han Chinese and Africans. All of these distinct traits give us a clue towards selective sweep on CYP3A4 locus in Han Chinese.
Thereby, both TD45 and FL-F46 tests were employed to test the observed mutation frequency distribution for deviations from neutral expectations. It is well known that the expected values of TD and FL-F are equal to zero under neutral equilibrium model. However, balancing selection or population subdivision may cause an excess of intermediate frequency variants and positive TD and FL-F values, whereas positive selection or population growth may lead to an excess of low frequency variants and negative TD and FL-F values.45, 46, 68 For the Han Chinese population, although the obtained negative value of TD failed to reach statistical significance (TD=−1.44935, P>0.10, Figure 3a), the bias in the spectrum of allele frequencies measured by FL-F test is significant (FL-F=−2.43436, P<0.05, Figure 3b), which indicates that the CYP3A4 locus is subject to positive selection in Han Chinese.
To obtain more evidence of positive selection, we used FW-H test47 on the basis of the excess of high-frequency-derived alleles, immediately after a selective sweep. FW-H test statistic is also expected to be negative, whereas the target of selection is typically within the deepest valley of the statistic.47 Indeed, the FW-H test statistic is negative across the CYP3A4 locus (FW-H=−2.65457, normalized FW-H=−2.19284), further confirming a recent episode of positive selection on CYP3A4. Moreover, we observed two prominent valleys in the FW-H statistic, with the deeper one in the locus of CYP3A4*1B (Figure 3c), implying the derived allele of CYP3A4*1B that promotes interaction with transcription repressors and leads to a decrease in CYP3A4 gene expression that has been favored by natural selection in the Han Chinese population. Our results are consistent with previous findings of detecting a selection against the CYP3A4*1B allele.13
Notably, the minor valley of the FW-H statistic occurs on the SNP rs2242480 (Figure 3c). To assess the evolutionary characteristics of this polymorphism, we conducted integrated haplotype score (iHS) statistic48 by Phase II HapMap data,69 a measure designed to detect extended haplotypes due to selective sweep. In principle, an extreme iHS value (∣iHS∣>2) of an SNP allele can be taken as evidence for a powerful selection signal.48 However, the iHS value is 0.443 in Africans (YRI), −0.756 in East Asians (ASN) and −1.591 in Europeans (CEU), respectively. The decay of extended haplotype homozygosity in YRI, ASN and CEU is shown in Figure 4. None of them display deviation from neutral expectation. Hence, the SNP rs2242480 is possibly neutral or may be influenced by genetic hitchhiking effect.
In addition, according to the ‘solid spine of LD’ method,34 the 11 SNPs formed a single LD block (D′>0.9), spanning 27 kb of the CYP3A4 locus (Figure 5). As the presence of intense LD is a strong signature of recent selective sweep,70 it also supports a role for positive selection on CYP3A4 in the Han Chinese population.
Taken together, our results confirm that the unusual low polymorphism levels and the skew towards rare variants of CYP3A4 gene in Han Chinese could be caused by the action of positive selection.
References
Nicolas, J. M., Espie, P. & Molimard, M. Gender and interindividual variability in pharmacokinetics. Drug. Metab. Rev. 41, 408–421 (2009).
Wilkinson, G. R. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin. Pharmacol. Ther. 76, 99–103 (2004).
Ozdemir, V., Kalow, W., Tang, B. K., Paterson, A. D., Walker, S. E., Endrenyi, L. et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373–388 (2000).
Perera, M. A. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert. Opin. Drug. Metab. Toxicol. 6, 17–28 (2010).
Kedmi, M., Maayan, S., Cohen, S. B., Hauzi, M. & Rund, D. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease. AIDS. Patient. Care. STDS. 21, 653–658 (2007).
Rebbeck, T. R., Troxel, A. B., Norman, S., Bunin, G., DeMichele, A., Schinnar, R. et al. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am. J. Epidemiol. 166, 1392–1399 (2007).
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J. & Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer. Inst. 90, 1225–1229 (1998).
Tayeb, M. T., Clark, C., Sharp, L., Haites, N. E., Rooney, P. H., Murray, G. I. et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol. Rep. 9, 653–655 (2002).
Yamada, Y., Matsuo, H., Watanabe, S., Kato, K., Yajima, K., Hibino, T. et al. Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Int. J. Mol. Med. 20, 703–707 (2007).
Kang, Y. S., Park, S. Y., Yim, C. H., Kwak, H. S., Gajendrarao, P., Krishnamoorthy, N. et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin. Pharmacol. Ther. 85, 312–318 (2009).
Liu, C. H., Peck, K., Huang, J. D., Lin, M. S., Wang, C. H., Hsu, W. P. et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 6, 731–747 (2005).
Garsa, A. A., McLeod, H. L. & Marsh, S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC. Med. Genet. 6, 19 (2005).
Schirmer, M., Toliat, M. R., Haberl, M., Suk, A., Kamdem, L. K., Klein, K. et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet. Genomics 16, 59–71 (2006).
Amirimani, B., Ning, B., Deitz, A. C., Weber, B. L., Kadlubar, F. F. & Rebbeck, T. R. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42, 299–305 (2003).
Hu, Y. F., He, J., Chen, G. L., Wang, D., Liu, Z. Q., Zhang, C. et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin. Chim. Acta. 353, 187–192 (2005).
Lee, S. J., Lee, S. S., Jeong, H. E., Shon, J. H., Ryu, J. Y., Sunwoo, Y. E. et al. The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug. Metab. Dispos. 35, 2095–2101 (2007).
Yamamoto, T., Nagafuchi, N., Ozeki, T., Kubota, T., Ishikawa, H., Ogawa, S. et al. CYP3A4*18: it is not rare allele in Japanese population. Drug. Metab. Pharmacokinet. 18, 267–268 (2003).
Ruzilawati, A. B., Suhaimi, A. W. & Gan, S. H. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin. Chim. Acta. 383, 158–162 (2007).
Westlind-Johnsson, A., Hermann, R., Huennemeyer, A., Hauns, B., Lahu, G., Nassr, N. et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79, 339–349 (2006).
Zhao, T. M. & Lee, T. D. Gm and Km allotypes in 74 Chinese populations: a hypothesis of the origin of the Chinese nation. Hum. Genet. 83, 101–110 (1989).
Chu, J. Y., Huang, W., Kuang, S. Q., Wang, J. M., Xu, J. J., Chu, Z. T. et al. Genetic relationship of populations in China. Proc. Natl. Acad. Sci. USA 95, 11763–11768 (1998).
Wen, B., Li, H., Lu, D., Song, X., Zhang, F., He, Y. et al. Genetic evidence supports demic diffusion of Han culture. Nature 431, 302–305 (2004).
Gan, R. J., Pan, S. L., Mustavich, L. F., Qin, Z. D., Cai, X. Y., Qian, J. et al. Pinghua population as an exception of Han Chinese's coherent genetic structure. J. Hum. Genet. 53, 303–313 (2008).
Hsieh, K. P., Lin, Y. Y., Cheng, C. L., Lai, M. L., Lin, M. S., Siest, J. P. et al. Novel mutations of CYP3A4 in Chinese. Drug. Metab. Dispos. 29, 268–273 (2001).
Wen, S., Wang, H., Ding, Y., Liang, H. & Wang, S. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet. Test. 8, 411–416 (2004).
Du, J., Xing, Q., Xu, L., Xu, M., Shu, A., Shi, Y. et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7, 831–841 (2006).
International HapMap Consortium. The International HapMap Project. Nature 426, 789–796 (2003).
Zhou, Q., Yu, X. M., Lin, H. B., Wang, L., Yun, Q. Z., Hu, S. N. et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 9, 380–394 (2009).
Lahiri, D. K. & Nurnberger, J. I. Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic. Acids. Res. 19, 5444 (1991).
Ewing, B., Hillier, L., Wendl, M. C. & Green, P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome. Res. 8, 175–185 (1998).
Ewing, B. & Green, P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome. Res. 8, 186–194 (1998).
Nickerson, D. A., Tobe, V. O. & Taylor, S. L. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic. Acids. Res. 25, 2745–2751 (1997).
Gordon, D., Abajian, C. & Green, P. Consed: a graphical tool for sequence finishing. Genome. Res. 8, 195–202 (1998).
Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005).
Abecasis, G. R. & Cookson, W. O. GOLD—graphical overview of linkage disequilibrium. Bioinformatics 16, 182–183 (2000).
Stephens, M., Smith, N. J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989 (2001).
Stephens, M. & Scheet, P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76, 449–462 (2005).
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U. & Segal, E. The role of site accessibility in microRNA target recognition. Nat. Genet. 39, 1278–1284 (2007).
Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R. et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome. Res. 13, 2129–2141 (2003).
Thomas, P. D. & Kejariwal, A. Coding single-nucleotide polymorphisms associated with complex vs Mendelian disease: evolutionary evidence for differences in molecular effects. Proc. Natl. Acad. Sci USA 101, 15398–15403 (2004).
Ramensky, V., Bork, P. & Sunyaev, S. Human non-synonymous SNPs: server and survey. Nucleic. Acids. Res. 30, 3894–3900 (2002).
Ekroos, M. & Sjogren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA 103, 13682–13687 (2006).
Binkowski, T. A., Naghibzadeh, S. & Liang, J. CASTp: Computed Atlas of Surface Topography of proteins. Nucleic. Acids. Res. 31, 3352–3355 (2003).
Librado, P. & Rozas, J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics 25, 1451–1452 (2009).
Tajima, F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123, 585–595 (1989).
Fu, Y. X. & Li, W. H. Statistical tests of neutrality of mutations. Genetics 133, 693–709 (1993).
Fay, J. C. & Wu, C. I. Hitchhiking under positive Darwinian selection. Genetics 155, 1405–1413 (2000).
Voight, B. F., Kudaravalli, S., Wen, X. & Pritchard, J. K. A map of recent positive selection in the human genome. PLoS. Biol. 4, e72 (2006).
Yu, Z., Li, Z., Jolicoeur, N., Zhang, L., Fortin, Y., Wang, E. et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic. Acids. Res. 35, 4535–4541 (2007).
Chen, K. & Rajewsky, N. Natural selection on human microRNA binding sites inferred from SNP data. Nat. Genet. 38, 1452–1456 (2006).
Gao, Y., Zhang, L. R. & Fu, Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur. J. Clin. Pharmacol. 64, 877–882 (2008).
Cavaco, I., Gil, J. P., Gil-Berglund, E. & Ribeiro, V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41, 1345–1350 (2003).
Chowbay, B., Zhou, S. & Lee, E. J. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug. Metab. Rev. 37, 327–378 (2005).
Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T. et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23, 100 (2004).
Mizutani, T. PM frequencies of major CYPs in Asians and Caucasians. Drug. Metab. Rev. 35, 99–106 (2003).
Thompson, E. E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B. A. & Di Rienzo, A. CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75, 1059–1069 (2004).
Du, J., Yu, L., Wang, L., Zhang, A., Shu, A., Xu, L. et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin. Chim. Acta. 383, 172–174 (2007).
Yamaguchi, Y., Khan, K. K., He, Y. A., He, Y. Q. & Halpert, J. R. Topological changes in the CYP3A4 active site probed with phenyldiazene: effect of interaction with NADPH-cytochrome P450 reductase and cytochrome b5 and of site-directed mutagenesis. Drug. Metab. Dispos. 32, 155–161 (2004).
Ohkura, K., Kawaguchi, Y., Watanabe, Y., Masubuchi, Y., Shinohara, Y. & Hori, H. Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket. Anticancer. Res. 29, 935–942 (2009).
Brennecke, J., Stark, A., Russell, R. B. & Cohen, S. M. Principles of microRNA-target recognition. PLoS. Biol. 3, e85 (2005).
Budhu, A., Jia, H. L., Forgues, M., Liu, C. G., Goldstein, D., Lam, A. et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897–907 (2008).
Navon, R., Wang, H., Steinfeld, I., Tsalenko, A., Ben-Dor, A. & Yakhini, Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS. One 4, e8003 (2009).
Simion, A., Laudadio, I., Prévot, P. P., Raynaud, P., Lemaigre, F. P., Jacquemin, P. et al. MiR-495 and miR-218 regulate the expression of the Onecut transcription factors HNF-6 and OC-2. Biochem. Biophys. Res. Commun. 391, 293–298.
Pogribny, I. P., Tryndyak, V. P., Ross, S. A. & Beland, F. A. Differential expression of microRNAs during hepatocarcinogenesis induced by methyl deficiency in rats. Nutr. Rev. 66, S33–S35 (2008).
Wong, Q. W., Lung, R. W., Law, P. T., Lai, P. B., Chan, K. Y., To, K. F. et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135, 257–269 (2008).
Mishra, P. J., Humeniuk, R., Longo-Sorbello, G. S., Banerjee, D. & Bertino, J. R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104, 13513–13518 (2007).
Chen, K., Song, F., Calin, G. A., Wei, Q., Hao, X. & Zhang, W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 29, 1306–1311 (2008).
Tajima, F. DNA polymorphism in a subdivided population: the expected number of segregating sites in the two-subpopulation model. Genetics 123, 229–240 (1989).
Consortium, T. I. H. A haplotype map of the human genome. Nature 437, 1299–1320 (2005).
Przeworski, M. The signature of positive selection at randomly chosen loci. Genetics 160, 1179–1189 (2002).
Acknowledgements
We thank Dr Jun Yu (Beijing Institute of Genomics, Chinese Academy of Sciences) for his valuable contribution. This work is supported by National Natural Science Foundation of China (No. 81001472) awarded to Qing Zhou.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on Journal of Human Genetics website
Rights and permissions
About this article
Cite this article
Zhou, Q., Yu, X., Shu, C. et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet 56, 415–422 (2011). https://doi.org/10.1038/jhg.2011.30
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhg.2011.30
Keywords
This article is cited by
-
Safety and Pharmacokinetics of PSD502 in Healthy Chinese Male and Female Volunteers: Two Randomized, Double-Blind, Placebo-Controlled, Phase I Trials
Clinical Drug Investigation (2023)
-
Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism
Archives of Toxicology (2023)
-
Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study
BMC Anesthesiology (2021)
-
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
International Journal of Hematology (2021)
-
Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes
European Journal of Clinical Pharmacology (2021)